摘要
Abstract
Objective This study aims to explore the therapeutic effect of preoperative neoadjuvant chemotherapy combined with Carolizumab on locally advanced esophageal cancer patients and its impact on prognosis.Methods A retrospective analysis was conducted on the clinical data of 60 patients with locally advanced esophageal cancer who underwent surgical treatment in Puyang City People′s Hospital from January 2020 to January 2024.According to the preoperative neoadjuvant treatment method of the patients,they were divided into immunotherapy group(preoperative combination of Carolizumab and neoadjuvant chemotherapy)of 35 cases,and control group(preoperative only receiving neoadjuvant chemotherapy)of 25 cases.Comparison of treatment outcomes,immune function,adverse effects and postoperative complications between the two groups.Results The results showed that the pCR、DCR and ORR of the immunotherapy group were significantly higher than those of the control group(P<0.05);there were no significant difference between the two groups in the operation time of R0 resection,R1 resection and surgical treatment(P>0.05);Before treatment,there was no statistically significant difference in CD3+and CD4+/CD8+between the two groups of patients(P>0.05);Compared within the group,after treatment,the levels of CD3+and CD4+/CD 8+in both groups of patients increased compared to before treatment,and the increase was more significant in the immunotherapy group(P<0.05);In the cohort undergoing immunotherapy,the rate of adverse events was marginally elevated in comparison to the control group.Similarly,the prevalence of overall complications was modestly increased within the immunotherapy cohort.Yet,when statistical analysis was applied,these variations did not reach a level of significance that would distinguish the two groups distinctly(P>0.05).Conclusion In the context of managing locally advanced esophageal carcinoma,the integration of preoperative neoadjuvant chemotherapy with the monoclonal antibody karelizumab demonstrates a favorable safety profile.This therapeutic approach not only enhances the immune response and the overall survival rate among patients but also does not elevate the risk of postoperative adverse events.Consequently,this regimen merits consideration for broader clinical implementation.关键词
局部晚期食管癌/免疫治疗/新辅助化疗/免疫功能/并发症Key words
locally advanced esophageal cancer/immunotherapy/neoadjuvant chemotherapy/immune function/complications分类
医药卫生
